- Clinical Trials
- April 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- May 2024
- 129 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- July 2024
- 180 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2022
- 200 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- February 2024
- 180 Pages
Global
From €4742EUR$4,969USD£3,973GBP
Cystinuria is a rare inherited disorder that affects the kidneys and causes an excessive amount of the amino acid cystine to be excreted in the urine. As a result, cystine crystals can form in the kidneys, bladder, and ureters, leading to painful and potentially dangerous kidney stones. Urological disorder drugs are used to treat cystinuria and reduce the risk of kidney stones. These drugs work by reducing the amount of cystine in the urine, allowing it to be more easily excreted.
The cystinuria drug market is a small but growing segment of the urological disorder drugs market. It is driven by the increasing prevalence of cystinuria and the need for effective treatments. The market is expected to grow at a steady rate over the coming years, as new treatments are developed and more people are diagnosed with the disorder.
Some companies in the cystinuria drug market include Allergan, AstraZeneca, Merck, and Pfizer. Show Less Read more